|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the potential uses of serum S100B protein as a biomarker in melanoma patients.
|
29135116 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Flow cytometric analysis of individual cells of two melanoma cell lines and the rat glioma cell line C6 indicated that G0/G1 cells were heterogeneous with respect to S100 protein expression, while almost all the cells in S + G2 + M expressed S100 protein.
|
2298261 |
1990 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
S100beta is an established biomarker of disease progression; however, the mechanism of its regulation in melanoma is undefined.
|
21654685 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, elevated S100B contributes to abnormal ERK/RSK signaling and increased cell survival in malignant melanoma.
|
24627490 |
2014 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
S100B levels in PB were dependent on the stage of melanoma disease and there was a significant shorter survival time in the group of patients with elevated S100B compared with the group with normal S100B values, (log rank test: P=0.04).
|
18337650 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Common histopathologic features are melanic pigment (<i>n</i> = 19/20), positive Human Melanoma Black (HMB-45) marker (<i>n</i> = 13/20), positive S100 protein reactivity (<i>n</i> = 11/20), as well as positive Melan-A (<i>n</i> = 9/20).
|
29649851 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
S100, human melanoma black 45, and melanoma antigen recognized by t-cell (Melan A) were negative.
|
30978337 |
2020 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated LDH is a BRAF-independent prognostic parameter; S100B has prognostic significance in BRAFwt melanoma only.
|
26659191 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers.
|
16054123 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
S100 calcium-binding proteins such as S100B are elevated in primary malignant melanoma and are used as markers for this and numerous other cancers.
|
15178678 |
2004 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
S100 remains as the most reliable routine marker to reach the diagnosis of melanoma in spindle cell and desmoplastic melanoma.
|
24051699 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum S100B Levels in Melanoma.
|
30710305 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The S100B protein, which is clinically used as the pathology identifier of MM, was identified in 9 out of 10 MM tissue lysates.
|
24490776 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is a substantial reduction in S-100+ LC and a lesser decline in CD1+ LC in the epidermis over melanoma.
|
7680054 |
1993 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, uveal melanomas appeared to express S100 beta protein less frequently and to a lesser degree.
|
8225871 |
1993 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The observed differences in expression patterns of the 3 S100 genes suggest distinct roles of their products in melanoma tumorigenesis and/or metastasis, and the results encourage studies to evaluate the potential value of using S100A2 and S100A6 expression levels as markers in the clinical management of melanoma.
|
9291441 |
1997 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In 15 melanoma patients there was a transient rise in the level of serum S100B at the beginning of systemic therapy.
|
12569284 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
|
27633490 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clear cell sarcomas and melanomas were also examined for their immunoreactivity to S-100 protein and HMB-45 antigen.
|
2004337 |
1991 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both in vitro and in vivo, the cells reacted with anti-S-100 protein and melanoma-specific HMB 45 antibodies by immunohistochemistry.
|
8492224 |
1993 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was a suggestion of reduced LI in normal skin in the proximity of melanoma (from melanoma re-excision specimens) for S100, HMB45 and TRPM1 mRNA.
|
20482673 |
2010 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates the ploidy status and S100 and HMB45 expression in snake melanomas in connection to their morphology and clinical history.
|
9427046 |
1998 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeted S100 therapies are also potentially viable strategies in the context of melanoma.
|
30216200 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The demonstration of an association and colocalization of S100B and S100A6 in melanoma supports the possibility that an S100B/S100A6 heterodimer plays a functional role in these cells.
|
9925766 |
1999 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, reducing S100B expression with siRNA was sufficient to activate p53, its transcriptional activation activities, and p53-dependent apoptosis pathway(s) in melanoma involving the Fas death receptor and perhaps PIDD.
|
20587415 |
2010 |